01134nas a2200265   4500000000100000008004100001260001300042653001800055653001400073653002400087653002200111653001200133653002000145100001600165700001300181700001300194700001500207245005600222856005900278300001100337490000700348050001800355520048100373022001400854       2013                            d  c2013 Jan10aUnited States10aTreatment10aMultidrug-resistant10aMultidrug therapy10aleprosy10aDrug Resistance1 aWilliams DL1 aHagino T1 aSharma R1 aScollard D00aPrimary multidrug-resistant leprosy, United States.  uhttp://wwwnc.cdc.gov/eid/article/19/1/pdfs/12-0864.pdf  a179-810 v19  aWILLIAMS 20133 aTO THE EDITOR: Since the initiation of multidrug therapy for leprosy (Hansen disease) in the 1980s by using rifampin, dapsone, and clofazimine, resistance to rifampin and dapsone has been observed worldwide and is still prevalent (1,2). Because few alternative effective antileprosy drugs exist, resistance to these first-line drugs could seriously affect leprosy control programs. We report a documented case of primary multidrug-resistant (MDR) leprosy in the United States.  a1080-6059